Censoring refers to a situation in survival analysis where the event of interest is not observed for some of the individuals under study.

In this Statistical Primer, we’ll define three types of censoring often seen in survival analysis studies.

Censoring occurs when the information on the survival time is incomplete or only partially observed.

Censoring can have a significant impact on the analysis and interpretation of survival data. It is essential to appropriately handle censoring in survival analysis to obtain accurate estimates of survival times, covariate effects, and other related parameters.

There are different types of censoring in survival analysis:

  • Right-censoring: This occurs when a participant is still alive or event-free at the end of the study period. In other words, the follow-up time for the participant ends before the event occurs. This is the most common type of censoring in survival analysis.
  • Left-censoring: This occurs when the true event time is known to be less than a certain time, but the exact time is unknown. For example, if an individual is diagnosed with a disease before the study begins but the date of onset of the disease is not known, we have left-censoring.
  • Interval-censoring: This occurs when the event time is known to fall within a certain interval, but the exact time of the event is unknown. For example, if a person develops glaucoma in between visits to the optician but the exact onset is unknown, we have interval censoring.

Latest Resources

Tutorials

Probabilistic sensitivity analysis and survival models

Today we’re going to take a little look into probabilistic sensitivity analysis (PSA), and how it can be implemented within the context of survival analysis. Now PSA is used extensively in health economic modelling, where a particular parameter (or parameters) of interest, are altered or varied, to represent different scenarios and levels of variation. We […]
Read more

Tutorials

Joint longitudinal and competing risks models: Simulation, estimation and prediction

This post takes a look at an extension of the standard joint longitudinal-survival model, which is to incorporate competing risks. Let’s start by formally defining the model. We will assume a continuous longitudinal outcome, $$y_{i}(t) = m_{i}(t) \epsilon_{i}(t)$$ where $$m_{i}(t) = X_{1i}(t)\beta_{1} + Z_{i}(t)b_{i}$$ and \(\epsilon_{i}(t)\) is our normally distributed residual variability. We call \(m_{i}(t)\) our […]
Read more

Tutorials

Simulation, modelling and prediction with a non-linear covariate effect in survival analysis

Let’s begin. There will be a single continuous covariate, representing age, with a non-linear effect influencing survival. We’ll simulate survival times under a data-generating model that incorporates a non-linear effect of age. We’ll then fit some models accounting for the non-linear effect of age, and finally make predictions for specified values of age. Sounds simple, […]
Read more

Tutorials

Simulation and estimation of three-level survival models: IPD meta-analysis of recurrent event data

In this example I’ll look at the analysis of clustered survival data with three levels. This kind of data arises in the meta-analysis of recurrent event times, where we have observations (events or censored), k (level 1), nested within patients, j (level 2), nested within trials, i (level 3). Random intercepts The first example will […]
Read more

Specialist subjects

Applied Biostatistics

Applied Biostatistics Biostatistics plays a crucial role in advancing medical research. Whether it’s clinical trials, epidemiological studies, or pre-clinical research, biostatistics is essential for drawing meaningful, impactful conclusions from complex data. Our team consists of internationally recognized experts in applied biostatistics, with deep experience in a wide range of areas such as survival analysis, multi-state […]
Read more

Tutorials

Defining a transition matrix for multi-state modelling

In this post we’ll take a look at how to define a custom transition matrix for use with our multistate package in Stata. The transition matrix A transition matrix governs the movement of a process between possible states. Within multi-state survival analysis, and particularly, the implementation of multi-state models in Stata, the transition matrix contains the most […]
Read more

Statistical Primers

What are competing risks?

Competing risks In survival analysis, competing risks refer to the situation when an individual is at risk of experiencing an event that precludes the event under study to occur. Competing risks commonly occur in studies of cause-specific mortality, as all other causes of death than the one under study might happen before the individuals “have […]
Read more

Specialist subjects

Haematology

Haematological malignancies At Red Door Analytics, we have extensive experience in working with haematological malignancies, demonstrated through 18 publications in peer-reviewed journals. Our expertise spans epidemiological studies on prognosis and late effects, as well as randomised clinical trials. Based in Stockholm, we have unique experience in accessing and working with registry data from the Nordic […]
Read more

Specialist subjects

Methods Development

Methods Development We provide expert guidance in finding the appropriate statistical approach to answer your question… and if there isn’t yet a method, well, we can develop one. While applying biostatistics to address your research question is essential, there may be times when existing methods fall short for your specific problem. In such cases, we’re […]
Read more

Statistical Primers

What is the Cox model?

The Cox model The Cox model, also known as the proportional hazards model, is a popular statistical tool used to analyse survival data. It was developed by British statistician Sir David Cox, and published in 1972. It has gained popularity largely by avoiding making parametric assumptions about the shape of the baseline rate in a […]
Read more

Specialist subjects

Clinical Trial Services

Clinical Trial Services Biostatistics services of RDA are the cornerstone of clinical trial design, execution, and interpretation. Biostatistical support by RDA will ensure that your clinical development programme and inherent studies are scientifically rigorous, appropriately powered, and capable of generating reliable evidence for regulatory approval and clinical use. RDA’s expertise for clinical development is focused […]
Read more

Tutorials

A user-defined/custom hazard model

This tutorial will illustrate some of the more advanced capabilities of merlin when modelling survival data, but with the aim of using an accessible example. During my PhD, Paul Lambert and I developed stgenreg in Stata for modelling survival data with a general user-specified hazard function, with the generality achieved by using numerical integration to calculate the cumulative hazard […]
Read more
All Resources